Chondrosarcoma - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chondrosarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chondrosarcoma: Overview
Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20 percent of all primary malignant tumors of the bone and usually arise in the pelvis or long bones. Primary or conventional chondrosarcoma arises in preexisting normal bone and is distinguished from the rarer secondary tumors, which occur within a preexisting enchondroma or osteochondroma. The majority of chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. As with many cancers, the cause of chondrosarcoma is not clear. However, people with certain medical conditions have an increased risk for developing chondrosarcoma. People with chondrosarcoma usually do not feel sick. They may be able to feel a boney bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor. A bone tumor is often first discovered on x-ray after a physical exam. It can be difficult to tell the difference between a benign bone tumor and chondrosarcoma on x-ray. Additional tests, including a bone scan, CT scan, MRI and PET scan, can provide more information about the tumor. Ultimately, biopsy of the tumor is the only way to make a definite diagnosis of chondrosarcoma. Complete surgical removal of the tumor, along with a wide margin of healthy tissue, has historically been the preferred treatment of chondrosarcoma.
'Chondrosarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chondrosarcoma Emerging Drugs
Further product details are provided in the report……..
Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.
Chondrosarcoma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chondrosarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Chondrosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chondrosarcoma: Overview
Chondrosarcomas are malignant cartilaginous neoplasms with diverse morphological features and clinical behavior. They account for about 20 percent of all primary malignant tumors of the bone and usually arise in the pelvis or long bones. Primary or conventional chondrosarcoma arises in preexisting normal bone and is distinguished from the rarer secondary tumors, which occur within a preexisting enchondroma or osteochondroma. The majority of chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. As with many cancers, the cause of chondrosarcoma is not clear. However, people with certain medical conditions have an increased risk for developing chondrosarcoma. People with chondrosarcoma usually do not feel sick. They may be able to feel a boney bump, and most patients ultimately will have pain, swelling, or limited movement that is caused by the tumor. A bone tumor is often first discovered on x-ray after a physical exam. It can be difficult to tell the difference between a benign bone tumor and chondrosarcoma on x-ray. Additional tests, including a bone scan, CT scan, MRI and PET scan, can provide more information about the tumor. Ultimately, biopsy of the tumor is the only way to make a definite diagnosis of chondrosarcoma. Complete surgical removal of the tumor, along with a wide margin of healthy tissue, has historically been the preferred treatment of chondrosarcoma.
'Chondrosarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chondrosarcoma pipeline landscape is provided which includes the disease overview and Chondrosarcoma treatment guidelines. The assessment part of the report embraces, in depth Chondrosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chondrosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chondrosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Chondrosarcoma.
This segment of the Chondrosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chondrosarcoma Emerging Drugs
- INBRX-109: Inhibrx
- AG120: Agios Pharmaceuticals
Further product details are provided in the report……..
Chondrosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Chondrosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chondrosarcoma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chondrosarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chondrosarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chondrosarcoma drugs.
Chondrosarcoma Report Insights
- Chondrosarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chondrosarcoma drugs?
- How many Chondrosarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chondrosarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chondrosarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chondrosarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Chondrosarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
INBRX-109: Inhibrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
LY3410738: Eli Lilly and Company/ Loxo Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chondrosarcoma Key Companies
Chondrosarcoma Key Products
Chondrosarcoma- Unmet Needs
Chondrosarcoma- Market Drivers and Barriers
Chondrosarcoma- Future Perspectives and Conclusion
Chondrosarcoma Analyst Views
Chondrosarcoma Key Companies
Appendix
Executive Summary
Chondrosarcoma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
INBRX-109: Inhibrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I)
Comparative Analysis
LY3410738: Eli Lilly and Company/ Loxo Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Chondrosarcoma Key Companies
Chondrosarcoma Key Products
Chondrosarcoma- Unmet Needs
Chondrosarcoma- Market Drivers and Barriers
Chondrosarcoma- Future Perspectives and Conclusion
Chondrosarcoma Analyst Views
Chondrosarcoma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Chondrosarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chondrosarcoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chondrosarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chondrosarcoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
